Semaglutide [Peptide]

Description

What is Semaglutide?

Semaglutide (NN9535, OG217SC) is a synthetic 31-amino acid glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk, classified as a long-acting incretin mimetic and the longest-half-life GLP-1 receptor agonist to achieve clinical approval in injectable form. Its amino acid sequence is based on human GLP-1(7-37) with two modifications to the peptide backbone: substitution of alanine at position 8 with 2-aminoisobutyric acid (Aib8) to provide resistance to dipeptidyl peptidase-4 (DPP-4)-mediated cleavage, and substitution of arginine at position 34 with lysine (R34K) to provide an acylation site. A C18 fatty diacid moiety (octadecanedioic acid) is conjugated to the epsilon-amino group of Lys34 via two 8-amino-3,6-dioxaoctanoic acid (mini-PEG, OEG) linkers and a gamma-glutamic acid (γGlu) spacer, enabling non-covalent albumin binding that extends the half-life to approximately one week in clinical pharmacokinetic studies — enabling once-weekly subcutaneous dosing.

Semaglutide is the most clinically validated and commercially deployed GLP-1 receptor agonist in history. It has received multiple FDA approvals across formulations and indications: Ozempic (subcutaneous injection) was approved on December 5, 2017 for glycaemic control in adults with type 2 diabetes; Rybelsus (oral tablet, with SNAC absorption enhancer) was approved September 20, 2019 for type 2 diabetes — the first oral GLP-1 receptor agonist; Wegovy (subcutaneous injection, 2.4 mg) was approved June 4, 2021 for chronic weight management; Wegovy received expanded approval in March 2024 to reduce the risk of major adverse cardiovascular events (MACE) in adults with cardiovascular disease and obesity; Wegovy received further approval for MASH (metabolic dysfunction-associated steatohepatitis) treatment; and oral Wegovy tablets were approved in December 2025. These approvals apply to pharmaceutical formulations manufactured under GMP conditions for defined clinical indications. Research-grade Semaglutide from RCDbio is not any of these pharmaceutical products and is not approved or intended for any human therapeutic use. It is not a dietary supplement and is not intended for human consumption or self-administration. All RCDbio research compounds are supplied strictly for laboratory and research purposes only.

Chemical Properties

Property	Detail
Product Type	Synthetic Long-Acting GLP-1 Receptor Agonist Peptide (Incretin Mimetic)
Product Name	Semaglutide
Application	Scientific / Research Use Only
CAS Number	910463-68-2
Molar Mass	4113.641 g/mol
Chemical Formula	C187H291N45O59
PubChem CID	56843331
IUPAC Name	Full canonical IUPAC available on PubChem CID 56843331; 31-residue GLP-1(7-37) backbone with Aib8, R34K substitutions, and C18 fatty diacid-OEG-OEG-γGlu conjugate at Lys34
Amino Acid Count	31 amino acids (GLP-1(7-37) backbone; Aib at position 8; Lys at position 34)
Key Modifications	Aib8: DPP-4 resistance; R34K: acylation site; C18 fatty diacid via OEG-OEG-γGlu linker at Lys34 epsilon-amino: albumin binding, half-life extension
Receptor Target	GLP-1R (glucagon-like peptide-1 receptor); high-affinity selective agonist; no significant GIPR or GCGR activity
Elimination Half-Life	~1 week (clinical PK studies; enables once-weekly dosing)
Synonyms	NN9535; OG217SC; NNC 0113-0217; Ozempic (pharmaceutical); Wegovy (pharmaceutical); Rybelsus (pharmaceutical)
FDA Approval Status	Multiple FDA approvals for pharmaceutical formulations: Ozempic (Dec 2017, T2D); Rybelsus (Sep 2019, T2D oral); Wegovy (Jun 2021, obesity; expanded 2024 MACE, MASH). Research-grade semaglutide from RCDbio is NOT a pharmaceutical product and is not approved or intended for human use.
Physical Form	Lyophilized white to off-white powder
Solubility	Soluble in sterile water and PBS; compatible with standard peptide reconstitution buffers
Storage (Lyophilized)	−20°C; sealed container; protected from light and moisture
Storage (Reconstituted)	4°C; use within 48–72 hours; avoid repeated freeze-thaw cycles
Purity	≥98% (HPLC verified, independent third-party laboratory analysis)
WADA Status	Semaglutide is NOT currently prohibited under the 2026 WADA Prohibited List. It is included in the 2026 WADA Monitoring Program — markers of semaglutide are monitored in- and out-of-competition to detect patterns of misuse, but it does not carry prohibited status. Research-grade non-pharmaceutical semaglutide may fall under S0 (Non-Approved Substances) provisions. Verify current status at GlobalDRO.com before use.

How Does Semaglutide Work?

Semaglutide mediates its effects through selective, high-affinity agonism at the GLP-1 receptor (GLP-1R), a class B (secretin family) GPCR expressed predominantly on pancreatic beta cells, the hypothalamus, brainstem, gastrointestinal tract, and cardiovascular tissues.

GLP-1R Gαs/cAMP/PKA Pathway and Glucose-Dependent Insulin Secretion

Semaglutide binds GLP-1R with approximately threefold greater binding affinity than endogenous GLP-1 due to its structural modifications. Receptor activation initiates Gαs-coupled signalling, generating elevated intracellular cyclic AMP (cAMP) and subsequent protein kinase A (PKA) activation in pancreatic beta cells. This pathway stimulates glucose-dependent insulin secretion — critically, insulin release is amplified only in the presence of elevated glucose, providing a safety advantage by reducing hypoglycaemia risk in the absence of concomitant insulin secretagogue use. Concurrent GLP-1R-mediated suppression of glucagon secretion from pancreatic alpha cells reduces hepatic glucose production, contributing to HbA1c lowering in clinical populations [Marso et al., 2016].

Hypothalamic Appetite Regulation

In hypothalamic and brainstem GLP-1R-expressing nuclei, semaglutide activates appetite-suppressive circuits including the arcuate nucleus (ARC), ventromedial hypothalamus (VMH), and nucleus tractus solitarius (NTS). In preclinical rodent models and clinical populations, GLP-1R activation in these regions reduces food intake, slows gastric emptying, and increases satiety signalling via direct neuronal effects. Long-term appetite reduction rather than increased metabolism has been characterised as the primary driver of the body weight reduction observed with semaglutide in STEP programme clinical trials [Wilding et al., 2021].

Albumin Binding and Half-Life Extension

The C18 fatty diacid moiety at Lys34 binds non-covalently but with high affinity to circulating albumin, reducing renal filtration and extending semaglutide’s half-life to approximately one week — compared to minutes for endogenous GLP-1. This albumin binding equilibrium also protects the peptide backbone from proteolytic degradation. The Aib8 substitution provides additional protection against DPP-4 cleavage at the His-Aib site in plasma, further extending systemic exposure.

Cardiovascular and Hepatic Pathway Effects

In clinical and preclinical preparations, semaglutide has been associated with direct cardioprotective effects independent of glycaemic control, including anti-inflammatory signalling in cardiac and vascular tissue, reduction of atherosclerotic plaque markers, and improved endothelial function. The SELECT trial (17,604 participants) demonstrated a 20% reduction in MACE risk. In hepatocyte and liver model preparations, semaglutide has been investigated for the reduction of hepatic lipid accumulation, steatohepatitis markers, and fibrosis pathway modulation, supporting its investigation and subsequent approval for MASH.

Key Research Findings

In preclinical, in vitro, and clinical research contexts, semaglutide has been associated with the following observations:

• SUSTAIN 6 cardiovascular outcomes: In 3,297 adults with T2D and established CVD, semaglutide reduced MACE composite by 26% versus placebo (HR 0.74; 95% CI 0.58–0.95) over 2.1 years — the trial supporting Wegovy’s cardiovascular indication [Marso et al., 2016].
• STEP 1 obesity trial: In 1,961 adults without diabetes, semaglutide 2.4 mg weekly produced 14.9% mean body weight reduction at 68 weeks versus 2.4% for placebo, with 86.4% of participants achieving ≥5% weight loss [Wilding et al., 2021].
• Oral bioavailability: Rybelsus (oral semaglutide with SNAC absorption enhancer) achieved clinically significant GLP-1R agonism orally — the first oral GLP-1 receptor agonist to reach approval, demonstrating that peptide GLP-1R agonism is achievable via the gastrointestinal route with appropriate formulation.
• MASH resolution: Clinical trial data demonstrated semaglutide-associated NASH resolution and fibrosis stage improvement in biopsy-confirmed MASH patients, supporting the MASH indication expansion.
• Thyroid C-cell neoplasm risk (rodents): In rodent 2-year carcinogenicity studies, GLP-1R agonists, including semaglutide, produced thyroid C-cell adenomas and carcinomas; human clinical relevance not established; patients with personal or family history of medullary thyroid carcinoma were excluded from trials.

All preclinical findings are from in vitro and in vivo animal model data. Clinical findings relate to pharmaceutical formulations at defined doses in approved clinical trial protocols. Research-grade Semaglutide from RCDbio is not a pharmaceutical product and is not approved or intended for human use. These observations do not constitute evidence of safety or efficacy for research-grade material.

What are the Potential Research Applications of Semaglutide?

In controlled laboratory and clinical research environments, semaglutide has been investigated for the following research applications. These do not constitute claims of efficacy or safety for research-grade material outside approved clinical protocols.

GLP-1 Receptor Pharmacology and cAMP Pathway Studies Semaglutide serves as the primary high-affinity reference ligand for GLP-1R pharmacology investigations. It is employed in radioligand displacement assays, cAMP reporter systems, BRET/FRET signalling studies, and biased agonism characterisation experiments to define the pharmacological standard against which novel GLP-1R compounds are compared.

Obesity and Hypothalamic Appetite Circuit Research. In preclinical rodent models, semaglutide is employed to investigate hypothalamic appetite-regulatory circuit modulation, specifically ARC and NTS GLP-1R pathway activation and its relationship to food intake, satiety signalling, and body weight regulation. Research examines the contributions of direct hypothalamic effects versus peripheral gastric effects to the observed weight changes.

Incretin Biology and Pancreatic Beta Cell Research. In isolated islet and beta cell preparations, semaglutide is used as the GLP-1R agonist reference standard for studying glucose-dependent insulin secretion dynamics, cAMP-dependent exocytosis, beta cell survival signalling, and the relationship between GLP-1R activation and beta cell mass in preclinical T2D models.

Cardiovascular and Endothelial Pathway Studies. In vascular endothelial cell preparations and rodent atherosclerosis model systems, semaglutide is investigated for anti-inflammatory and cardioprotective pathway modulation, including NF-κB attenuation, ICAM-1/VCAM-1 downregulation, and plaque composition effects — research aimed at characterising the cardiovascular mechanism behind the SELECT trial outcomes.

Comparative GLP-1 Agonist Pharmacology. As the foundational single-receptor GLP-1R agonist against which dual (Tirzepatide, GIP/GLP-1) and triple (Retatrutide, GLP-1/GIP/GCG) agonists are compared, semaglutide anchors comparative pharmacology studies examining how additional receptor engagement alters metabolic, cardiovascular, and neurological outcomes in matched preclinical and clinical populations.

What are the Potential Side Effects of Semaglutide?

The following observations are from pharmaceutical formulation clinical trials. Research-grade material adverse effects have not been independently characterised.

• Gastrointestinal adverse events — nausea, vomiting, diarrhoea, constipation — most frequently reported across SUSTAIN and STEP trials; dose-dependent; predominantly mild-to-moderate; consistent with GLP-1R agonist class pharmacology
• Thyroid C-cell tumours in rodent 2-year carcinogenicity studies; human clinical relevance not established; patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) were excluded from pharmaceutical trials
• Pancreatitis risk cannot be excluded; GLP-1R agonist class association with pancreatitis; participants with a history of pancreatitis excluded from trials
• Gallbladder disease (cholelithiasis, cholecystitis) was reported at higher rates than placebo in clinical trial populations
• Transient heart rate increases noted, consistent with GLP-1R agonist class pharmacology
• No human safety or tolerability data have been established for research-grade semaglutide outside approved clinical trial protocols. Adverse event observations above are from pharmaceutical formulation trials and should not be extrapolated to research-grade material.

Risk & Handling

Handling Precautions

Research-grade Semaglutide should only be handled by trained laboratory personnel. Appropriate PPE is required: nitrile gloves, a laboratory coat, and eye protection at a minimum. When working with lyophilized powder, use within a laminar flow cabinet or a clean area. Avoid aerosol generation during reconstitution. The fatty acid conjugate moiety contributes amphiphilic character — avoid surfaces that adsorb lipophilic molecules.

Exposure Risks

Risk Tier: MODERATE

Semaglutide is a potent, long-acting GLP-1R agonist with a clinical half-life of approximately one week. Accidental systemic exposure at research concentrations could engage GLP-1R in pancreatic, hypothalamic, and gastrointestinal tissues, producing prolonged glucose-dependent insulin secretion effects, reduced appetite, gastrointestinal motility changes, and potential nausea. The one-week half-life means effects from accidental exposure would be protracted. No human safety data has been established for research-grade semaglutide outside clinical trial contexts.

Storage

• Lyophilized form: Store at −20°C in original sealed, light-protected container with desiccant
• Reconstituted form: Store at 4°C; use within 48–72 hours of reconstitution
• Do not subject to repeated freeze-thaw cycles; fatty acid conjugate and peptide backbone integrity may be affected
• Protect from prolonged light exposure and oxidative conditions
• Store away from strong acids, bases, and oxidising agents

Frequently Asked Questions

Q: What is Semaglutide, and what is it investigated for in research? A: Semaglutide (NN9535) is a synthetic 31-amino acid GLP-1 receptor agonist with a ~1-week half-life achieved through Aib8 DPP-4 resistance and C18 fatty acid albumin binding via OEG linkers. It is the foundational reference GLP-1R agonist in incretin pharmacology research and the primary clinical comparator for dual (tirzepatide) and triple (retatrutide) receptor agonists. Pharmaceutical formulations are FDA-approved for T2D (Ozempic, Rybelsus), obesity (Wegovy), cardiovascular risk reduction, and MASH. Research-grade semaglutide from RCDbio is not a pharmaceutical product and is not intended for human use.

Q: What are the FDA-approved formulations of semaglutide, and when were they approved? A: Ozempic (subcutaneous injection) — December 5, 2017, type 2 diabetes. Rybelsus (oral tablet with SNAC) — September 20, 2019, type 2 diabetes. Wegovy (2.4 mg subcutaneous injection) — June 4, 2021, chronic weight management; expanded March 2024 for MACE reduction; approved for MASH. Oral Wegovy tablets — December 2025. These approvals are for pharmaceutical formulations. Research-grade semaglutide from RCDbio is not any of these products and is not approved for human use.

Q: How does semaglutide achieve a half-life of approximately one week? A: Two structural features achieve this: the Aib8 substitution prevents DPP-4 enzymatic cleavage at the N-terminal His-Aib bond (vs. His-Ala in native GLP-1, which is the primary DPP-4 cleavage site); and the C18 fatty diacid at Lys34 via two OEG-OEG-γGlu linkers binds albumin non-covalently with high affinity, reducing renal filtration and proteolytic exposure. The resulting half-life of approximately one week in clinical PK studies enables once-weekly subcutaneous dosing in approved pharmaceutical protocols.

Q: How does semaglutide compare to tirzepatide? A: Semaglutide is a selective GLP-1R monoagonist. Tirzepatide adds GIPR agonism (dual GIP/GLP-1 agonist, twincretin). In head-to-head clinical trials (SURMOUNT-5, 2024), tirzepatide 15 mg produced significantly greater mean weight loss than semaglutide 2.4 mg (20.2% vs 13.7% at 72 weeks). Tirzepatide also demonstrated superior HbA1c reduction in SURPASS-2. At the GLP-1R, tirzepatide exhibits biased cAMP signalling vs semaglutide’s balanced agonism. Semaglutide remains the primary monotherapy reference compound for comparative incretin pharmacology.

Q: What were the key STEP 1 trial findings? 

In the STEP 1 Phase 3 randomised controlled trial (Wilding et al., 2021, NEJM), 1,961 adults without diabetes receiving semaglutide 2.4 mg weekly for 68 weeks achieved a mean body weight reduction of 14.9% versus 2.4% for placebo (difference −12.4 percentage points; p<0.001). 86.4% achieved ≥5% weight loss, 69.1% achieved ≥10%, and 50.5% achieved ≥15%. These data supported the Wegovy obesity indication.

Q: What is semaglutide’s WADA status? 

Semaglutide is not currently prohibited under the 2026 WADA Prohibited List. It is included in the 2026 WADA Monitoring Program — markers are tracked in- and out-of-competition to detect misuse patterns, but it does not carry prohibited status. Research-grade non-pharmaceutical semaglutide may fall under S0 (Non-Approved Substances) provisions. Pharmaceutical formulations (Ozempic, Rybelsus, Wegovy) may qualify for a Therapeutic Use Exemption (TUE) for specific medical conditions. Verify current status at GlobalDRO.com. 

Related Research Compounds

Researchers investigating Semaglutide may also be interested in the following compounds currently available for laboratory research at RCDbio:

• Tirzepatide — The dual GLP-1R/GIPR agonist (twincretin); the primary head-to-head clinical comparator for semaglutide and the reference compound for studying GIP receptor co-activation effects alongside GLP-1R pharmacology.
• Retatrutide — The triple GLP-1R/GIPR/GCGR agonist; the next-generation comparator for characterising how GCGR addition to GLP-1R/GIPR agonism alters metabolic, hepatic, and cardiovascular outcomes relative to semaglutide.

All products listed are for laboratory and research purposes only.

References

1. Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., Steinberg, W. M., Stockner, M., Zinman, B., Bergenstal, R. M., & Buse, J. B. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834–1844. https://pubmed.ncbi.nlm.nih.gov/27633186/

2. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://pubmed.ncbi.nlm.nih.gov/33567185/

3. Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., Strauss, H. M., Gram, D. X., Knudsen, S. M., Nielsen, F. S., Thøgersen, P., Reedtz-Runge, S., & Kruse, T. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry, 58(18), 7370–7380. https://pubmed.ncbi.nlm.nih.gov/26308095/  
4. Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., Tack, C. J., Thomsen, M., Vilsbøll, T., Warren, M. L., & Bain, S. C. (2019). Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 381(9), 841–851. https://pubmed.ncbi.nlm.nih.gov/31185157/ 

Disclaimer

Semaglutide is exclusively for laboratory research purposes. RCDbio products are not intended to diagnose, prevent, treat, or cure any disease or medical condition. Research-grade Semaglutide is not Ozempic, Wegovy, or Rybelsus, and is not equivalent to or interchangeable with any approved pharmaceutical formulation.

The Food and Drug Administration has approved semaglutide in multiple pharmaceutical formulations for defined clinical indications. Research-grade semaglutide from RCDbio is not an approved product and is not intended for human use in any form. Researchers must comply with all applicable local, state, and federal laws and regulations governing the purchase and use of research compounds. By purchasing, you agree to our Terms and Conditions. RCDbio reserves the right to refuse sales to unauthorized individuals.

ATTENTION: All RCDbio products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not intended for human consumption, veterinary use, or any other non-research application. For queries, complaints, or support, contact support@rcdbio.co